Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (irAE) (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot InitiativeSM that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers.

The purpose of this FOA is to support improved cancer immunotherapy research projects that reduce the incidence and/or severity of immune-related adverse events (irAEs) while retaining anti-tumor efficacy. Single investigators and/or multidisciplinary teams with expertise in mechanisms of cancer immunology, immune tolerance, irAEs, autoimmunity, and/or patient characterization and selection are encouraged to propose projects that utilize appropriate model systems, clinical samples, and expertise of these research communities. The specific objectives are to generate new ideas and approaches to better understand and thereby reduce the incidence and/or severity of irAEs resulting from cancer immunotherapy.

Depending on whether the scope of the irAE research is for adult or pediatric immunotherapy, these research projects will become components of the Immuno-Oncology Translational Network (IOTN) or the Pediatric Immunotherapy Discovery and Development Network (PI-DDN).


  • Letter of Intent Due Date(s): 30 days prior to the application due date.
  • Application Due Date(s): April 25, 2019

RFA-CA-19-044 Expiration Date April 26, 2019

Agency Website



Amount Description

Each application budget is limited to $375,000 in direct costs (exclusive of F&A consortium costs) per year.

The total project period may not exceed 5 years.

      Funding Type





      Medical - Basic Science

      External Deadline

      April 25, 2019